[Study on postoperative local chemotherapy of malignant brain tumors using ACNU and PSK].
There have been many attempts to treat patients with malignant brain tumors represented by glioblastomas using nitrosourea (NU) derivatives such as BCNU and CCNU but the clinical results are not so remarkable compared with previous reports concerning experimental studies. The reason for an efficacy of NU derivatives in brain tumors is considered to be its higher lipid solubility which makes the drug crossing the BBB easily. On the other hand, there is some evidence that higher lipid solubility did not guarantee NU to reach always to all portions of solid tumor after systemic administration. We have performed a chemotherapy of malignant brain tumors using ACNU for five years. This drug is not only lipid but also water-soluble in some grade; therefore, the drug is administrated intravascularly and locally with ease. Nine cases of malignant gliomas were treated with local chemotherapy employing ACNU and two cases of glioblastomas are surviving now over five years and about four years, respectively. From the anatomical standpoint of view, it is considered to be necessary for local chemotherapy of brain tumors to possess some pathognomonic characters such as cyst formations, central necrosis and localized cortico-meningeal adhesions, which are rather frequently found in malignant gliomas and are suspected also easily by CT examination preoperatively. A local chemotherapy in the present study has been performed using 10 to 50 mg of ACNU through an indwelling catheter inserted during operation. No general toxicity occurred in all patients except one, who experienced purulent meningitis after long-term drainage. In our study on concentration of ACNU, intracarotid injection resulted in higher concentration in brain tumor tissue than intravenous injection, but these concentration considered to be not high enough to suppress the tumor cell growth. On the other hand, the intracavitary concentration of ACNU at 24 hr after drug administration was high enough to suppress the tumor cell growth.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001254:Astrocytoma / Q000601:surgery / Q000628:therapy; D001932:Brain Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D002339:Carotid Arteries; D004359:Drug Therapy, Combination; D005260:Female; D005910:Glioma / Q000601:surgery / Q000628:therapy; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000008:administration & dosage*; D011184:Postoperative Period; D011509:Proteoglycans / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D011509:Proteoglycans; D015376:Nimustine; C010770:polysaccharide-K